Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma

Avan A, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ, Lagerweij T, Van Tellingen O, Campani D, Fuchs D, Verheul HM, Schuurhuis GJ, Boggi U, Peters GJ, Würdinger T, Giovannetti E
Cancer Res. 2013 Nov 15;73(22):6745-56

continue reading →

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare

MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity

Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, Danesi R, Campani D, Verheul HM, Boggi U
Cancer Res. 2010 Jun 1;70(11):4528-38

continue reading →

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare

Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, Del Tacca M, Peters GJ, Falcone A, Danesi R
Clin Cancer Res. 2008 Mar 15;14(6):1797-803

continue reading →

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine

Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R
Cancer Res. 2006 Apr 1;66(7):3928-35

continue reading →

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare

Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non–small-cell lung cancer cells

Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R
Mol Pharmacol. 2005 Jul;68(1):110-8

continue reading →

FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare